A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma - Full Text View

Purpose

This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma

Condition	Intervention	Phase
Asthma	Drug: FTY720 Drug: Placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Double-Blind, Randomized, Placebo-Controlled, Parallel, Time-Lagged, Ascending, Multi-Centre, Multiple-Dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma

Resource links provided by NLM:

Drug Information available for: Fingolimod Fingolimod hydrochloride

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Change from baseline in Pulmonary function tests (particularly Forced Expiratory Volume at 1 sec (FEV1) at Day 10 [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]
Safety of FTY720 [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Use of short acting beta agonists during treatment compared to pre-treatment [ Time Frame: 10 days ] [ Designated as safety issue: No ]
Pharmacokinetics of FTY720 and FTY720-P [ Time Frame: 10 days ] [ Designated as safety issue: No ]


Enrollment:	36
Study Start Date:	September 2008
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: FTY720
Placebo Comparator: 2	Drug: Placebo

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Forced Expiratory Volume in 1 second of at least 60%
History of asthma for at least 6 months
Current use of short-acting beta agonists, inhaled long-acting beta agonists and inhaled corticosteroids (up to a specified dose)

Exclusion Criteria:

History of lung disease other than asthma
Smokers
Use of inhaled corticosteroid above specified dose
Use of oral beta agonists or corticosteroids or other asthma medications
Hypersensitivity to the drug
Respiratory tract infections within 1 month of the study

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00785083

Locations


United Kingdom
Novartis Investigator Site
Manchester, United Kingdom

Sponsors and Collaborators

Novartis

Investigators


Principal Investigator:	Novartis	Novartis Investigator Site

More Information


Responsible Party:	External Affairs, Novartis
ClinicalTrials.gov Identifier:	NCT00785083 History of Changes
Other Study ID Numbers:	CFTY720D2102
Study First Received:	November 4, 2008
Last Updated:	May 8, 2009
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:


Asthma, adrenergic beta agonists, multiple sclerosis, pulmonary function tests, forced expiratory volume

Additional relevant MeSH terms:


Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate	Hypersensitivity Immune System Diseases Fingolimod Hydrochloride Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 29, 2016